Table 2.

Cardiac safety results in the adjuvant trastuzumab trials

RegimenMedian follow-up (y)Class III/IV congestive hear failure (% of patients)Systolic dysfunction (% of patients)Reference
HERAChemo→observation200.5(19)
Chemo→H × 1 y0.63
Chemo→H × 2 yNRNR
NCCTG 9831AC→P→observation30.34-5.1(20, 21)
AC→P→H2.84-7.8
AC→PH3.35.8-10.4
AC→P→observation0.9NR
AC→PH3.815.9
BCIRG 006AC→T→observation50.510(14)
AC→TH1.918
TCH0.48.6
Fin HERV→FEC or T→FEC3NR6(13)
VH→FEC or TH→FEC03.5
PACS 04FEC or ET→observation40.42.2(16)
FEC→H or ET→H1.74.2